Oritavancin is a lipoglycopeptide with activity against gram-positive pathogens including vancomycinresistant enterococci. The impact of human serum albumin (HSA) on oritavancin activity against enterococci was compared to those of vancomycin, daptomycin, teicoplanin, and linezolid in vitro using MIC and time-kill methods. Oritavancin MICs increased between 0-and 8-fold in the presence of HSA. In time-kill assays with HSA, oritavancin retained activity, killing or inhibiting enterococci more rapidly than did comparators when peak concentrations were simulated.
Oritavancin, a lipoglycopeptide with activity against drugresistant gram-positive bacteria, is 85 to 90% protein bound (11, 15) . Most of the binding of oritavancin in human serum is to albumin (15) . The effect of protein binding on the bactericidal activity of antimicrobial agents has been a source of controversy-arguments for protein binding either diminishing or augmenting the activity of agents have been advanced by different researchers, although it has been established that the free, unbound fraction is responsible for antimicrobial activity (3, 12) . Most in vitro antibiotic susceptibility tests and time-kill assays are performed with standard microbiological media, such as cation-adjusted Mueller-Hinton broth (CAMHB), without supplementation by serum or serum albumin. However, studies that take into account the influence of biological fluids, such as human serum or its purified constituents, on the activities of antibacterial agents in vitro may better predict in vivo drug efficacy. In this study, we have investigated the effect of human serum albumin (HSA) at physiological concentrations (14) on the in vitro activities of oritavancin and comparator antibiotics against reference strains and clinical isolates of enterococci. The tested strains represented vancomycin-susceptible and both VanA and VanB vancomycin-resistant isolates.
(Part of this work was presented at the joint meeting of the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Diseases Society of America 46th annual meeting, held at Washington, DC, 25 to 28 October 2008 [9] .)
Oritavancin concentrations (Table 1) were chosen to approximate the closest MIC doubling dilution to the total (protein bound plus unbound) peak (C max ) and total trough levels in plasma following administration of a 200-mg dose (6, 7, 13) .
Comparator drug concentrations (Table 1) were likewise chosen to approximate (to the closest MIC doubling dilution) their respective total C max and total trough levels in plasma when administered at FDA-approved dosages for complicated skin and skin structure infections (daptomycin, Cubicin insert; linezolid, Zyvox insert; vancomycin, Vancocin insert; teicoplanin, Targocid insert).
Predicted free drug concentrations in the presence of 4% (wt/vol) HSA (Table 1) were calculated as the product of the total peak or total trough concentration (Table 1 ) and the free fraction (Table 1) , as determined from protein binding data from the literature (11) or package inserts.
MICs against oritavancin, vancomycin, and teicoplanin were determined by the broth microdilution assay according to the CLSI M7-A7 and M100-S18 guidelines (4, 5) . Tests with oritavancin included polysorbate 80 (final test concentration of 0.002%) as described previously (1, 5): oritavancin was dissolved in 0.002% polysorbate 80 in water, and polysorbate 80 was maintained at this concentration in drug dilution steps and in the MIC assays. For assays with daptomycin, CAMHB was supplemented with 50 g/ml CaCl 2 (final concentration) (4).
Time-kill assays in the presence of 4% HSA were performed according to CLSI M26-A guidelines (10) with the following alteration: polymethylpentene Erlenmeyer flasks were used in an effort to minimize binding of oritavancin to vessel surfaces (2) . Exponential-phase cells were diluted to approximately 5 ϫ 10 5 to 1 ϫ 10 6 CFU/ml and exposed to oritavancin or comparator antibiotics over a 24-h period in a total volume of 12.5 ml of CAMHB plus 4% HSA. For assays with oritavancin, 0.002% polysorbate 80 (1) was included to minimize the loss of oritavancin to surfaces. For assays with daptomycin, CAMHB was supplemented with 50 g/ml CaCl 2 (final concentration) (4). Viable-cell counts were determined by serial dilution plating. Culture aliquots were mixed with a suspension of activated charcoal (25 mg/ml) to minimize antibiotic carryover. Bactericidal activity was defined as a Ն3-log decrease in cell counts compared to the inoculum (10). Assays were performed at least twice independently, with similar rates and extents of kill between experiments seen for oritavancin and for comparators; results presented are from a single experiment. All data points are an average of duplicate determinations within an experiment. Table 2 shows MIC results for oritavancin and comparators in the presence and absence of 4% HSA. Oritavancin MICs increased two-to eightfold in the presence of 4% HSA against five of the six isolates of enterococci; oritavancin MICs remained unchanged for Enterococcus faecium strain 1119175 (VanB vancomycin-resistant Enterococcus [VRE]) in the presence and absence of 4% HSA. Vancomycin and linezolid MICs against enterococci determined in the presence of 4% HSA remained unchanged, while teicoplanin and daptomycin MICs increased 2-to 8-fold and 8-to 16-fold, respectively, in the presence of 4% HSA. The extents of these HSA-induced MIC shifts for comparator agents against enterococci are similar to those reported for vancomycin, teicoplanin, and daptomycin using a similar approach for Staphylococcus aureus (12) .
Time-kill curves of oritavancin at its total peak or total trough concentration in the presence of 4% HSA were similar to previously reported time-kill data with predicted free peak or free trough concentrations of drug in CAMHB in the absence of albumin (8) . This suggests that the oritavancin serum protein binding value of 88% (11) that was used in calculations to represent free C max and free trough concentrations in vitro is useful for predicting actual free drug concentrations. The same was found to hold true for the comparator agents.
Oritavancin demonstrated concentration-dependent activities against the enterococci used in this study in the presence of 4% HSA (Table 3 and data not shown). This was expected, since oritavancin activity in vitro and in vivo against enterococci, streptococci, and staphylococci is best described as concentration dependent (8) . When tested in the presence of 4% HSA at drug concentrations approximating its total peak and total trough levels, oritavancin was the only compound that exerted bactericidal activity against vancomycin-susceptible Enterococcus (Table 3) . Furthermore, oritavancin was the only compound to retain bacteriostatic or bactericidal activity a Boldface with underlining indicates bactericidal activity (log kill at 24 h relative to starting inoculum is indicated); boldface alone indicates bacteriostatic activity (decrease or no change in log CFU/ml relative to starting inoculum at 24 h is indicated); lack of boldface indicates little or no inhibition of growth (increase in log CFU/ml relative to starting inoculum at 24 h is indicated). Ef, E. faecalis; Em, E. faecium; VSE, vancomycin-susceptible Enterococcus; VRE, vancomycin-resistant Enterococcus.
against all tested strains at the total peak concentration (Table  3 ). In the presence of 4% HSA, only oritavancin retained activity against the VanA (n ϭ 3) and VanB (n ϭ 2) VRE strains tested in this study (Table 3) . Linezolid demonstrated bacteriostatic activity at both peak and trough levels for all the strains tested.
The studies presented herein demonstrate that oritavancin retains in vitro activity against difficult-to-treat VRE in the presence of physiologically relevant levels of HSA and is a potential candidate in the treatment of infections caused by enterococci regardless of their glycopeptide susceptibility phenotype.
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